3/25
08:17 am
ubx
Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at Chardan Capital from $6.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at Chardan Capital from $6.00 to $4.00. They now have a "buy" rating on the stock.
3/10
08:58 am
ubx
Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Low
Report
Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
3/10
08:03 am
ubx
Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/10
08:00 am
ubx
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors
Medium
Report
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors
3/7
05:35 pm
ubx
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates [Yahoo! Finance]
3/7
04:30 pm
ubx
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Medium
Report
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
1/24
06:28 pm
ubx
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan [TechCrunch]
Low
Report
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan [TechCrunch]